These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
472 related items for PubMed ID: 21730794
21. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV. Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759 [Abstract] [Full Text] [Related]
25. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks. Yuan Y, Tan CW, Shen H, Yu JK, Fang XF, Jiang WZ, Zheng S. Hepatogastroenterology; 2012 Mar; 59(120):2461-5. PubMed ID: 22497949 [Abstract] [Full Text] [Related]
26. Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K. Dis Colon Rectum; 2014 Jan; 57(1):23-31. PubMed ID: 24316942 [Abstract] [Full Text] [Related]
27. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, AVIRI Trial investigators. Oncology; 2009 Jan; 77(2):113-9. PubMed ID: 19628950 [Abstract] [Full Text] [Related]
30. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G. Br J Cancer; 2011 Apr 12; 104(8):1262-9. PubMed ID: 21407216 [Abstract] [Full Text] [Related]
34. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K. Cancer; 2011 Sep 01; 117(17):4026-32. PubMed ID: 21858803 [Abstract] [Full Text] [Related]
35. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. Saif MW, Merritt J, Robbins J, Stewart J, Schupp J. Clin Colorectal Cancer; 2006 Sep 01; 6(3):229-34. PubMed ID: 17026795 [No Abstract] [Full Text] [Related]